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(CTLAAla17) and that this results in
inefficient glycosylation and decreased
cell-surface expression (Anjos et al.,
2002). Our association results show that
rs231775 was also strongly associated
with AA in our sample although the
P-values were less significant and
the ORs were lower than those for
rs3087243. Furthermore, conditional
analysis revealed that rs1427678
explained the entire association signal
at the locus.
In conclusion, our results provide
strong support for the hypothesis that
CTLA4 is a susceptibility gene for AA,
and they also suggest that it has the
strongest effect in patients with a severe
form of the disorder. Given the low
P-values observed in our study and
the genome-wide association study by
Petukhova et al. (2010), we consider
CTLA4 a proven susceptibility gene
for AA.
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Erythropoietic Uroporphyria Associated with Myeloid
Malignancy Is Likely Distinct from Autosomal Recessive
Congenital Erythropoietic Porphyria
Journal of Investigative Dermatology (2011) 131, 1172–1175; doi:10.1038/jid.2011.5; published online 17 February 2011
TO THE EDITOR
Congenital erythropoietic porphyria
(CEP; MIM 263700) is a rare autosomal
recessive disease caused by muta-
tions in uroporphyrinogen III synthase
(UROS) or, rarely, in GATA1 genes,
leading to UROS deficiency (Fritsch
et al., 1997; de Verneuil et al., 2003;
Phillips et al., 2007). The resulting
overproduction of type I porphyrin
isomers by erythroid cells causes severe
photosensitivity and hemolytic anemia.
Abbreviations: BFU, burst-forming unit; CEP, congenital erythropoietic porphyria; MDS, myelodysplastic
syndrome; UROS, uroporphyrinogen III synthase
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It usually presents in infancy; however,
13 patients have been reported who did
not present with the disease until
adulthood (Fritsch et al., 1997; Kontos
et al., 2003; de Verneuil et al., 2003).
Some of them had mild late-onset
autosomal recessive CEP (de Verneuil
et al., 2003); however, five of the seven
presenting with the disease after the age
of 50 years had an associated myeloid
malignancy, usually myelodysplastic
syndrome (MDS; Kontos et al., 2003).
We describe three new patients
(patients 1–3) aged 64–75 years with a
preexisting myeloid malignancy (Sup-
plementary Table S1 online), who sub-
sequently developed CEP (Table 1).
Archived blood samples were also
available from a previously reported
patient (patient 4; Murphy et al., 1995).
We show that these patients have a
disorder that, although similar to CEP,
is likely distinct, with biochemical
and molecular features that define it
as a separate condition, which we
term ‘‘erythropoietic uroporphyria sec-
ondary to myeloid malignancy’’. All
patients gave informed consent to
participate in the investigation. Institu-
tional approval for the study was
obtained as required. The study was
conducted in accordance with the
Declaration of Helsinki principles.
All four patients had bullae on the
back of their hands and produced
excess porphyrins in the characteristic
CEP pattern, but porphyrin concentra-
tions were lower than that in child-
hood-onset CEP (Table 1). Unlike
hereditary CEP, erythrocyte UROS ac-
tivity was normal (Table 1). We se-
quenced UROS genomic DNA from
peripheral blood obtained from these
patients and from 24 patients with
childhood-onset CEP (Supplementary
Materials and Methods online). UROS
mutations were identified in 19 of the
24 childhood-onset cases but in none
of our four MDS patients (Pp0.01),
implying that MDS-associated uropor-
phyria is not caused by a germline
UROS mutation. Deletion of one
UROS allele was also excluded by
demonstrating heterozygosity for a
single-nucleotide polymorphism in
intron 8 (rs2281955; patients 1–3)
and for single-nucleotide polymor-
phisms in exon 1, intron 5, and intron
8 (rs4256900, rs10901444, rs2281954,
and rs3740179; patients 2 and 3).
Fluorescence microscopic studies of
bone marrow aspirates from patients 1
and 2 showed that only B25% of
normoblasts had the characteristic red
nuclear fluorescence of uroporphyrin
(Figure 1a and b). We cultured burst-
forming unit–erythroid colonies from
the peripheral blood of patient 2; of
seven colonies picked at random, only
one showed red porphyrin fluorescence
(Figure 1c and d). We conclude that
the porphyric defect is present in only a
minority of hemopoietic cells.
Genomic instability of myeloid pro-
genitors in MDS causes gross chromo-
somal abnormalities and point
mutations. Bone marrow karyotyping
showed that patient 2 had a partial
deletion of chromosome 11q (break-
point in band q1.4), whereas patient 1
had no abnormalities. No deletions
of chromosome 10, which carries
UROS (q25.2–q26.3), were observed.
No UROS mutations were identified by
sequencing UROS genomic DNA (pa-
tients 1 and 2) or complementary DNA
(patient 1) from unfractionated bone
marrow cells. Both patients showed the
same single-nucleotide polymorphism
heterozygosity pattern in genomic DNA
Table 1. Metabolite and enzyme measurements in patients with uroporphyria
Patient
Age at onset of
myeloid disorder
(years)
Age at onset of
bullous skin
lesions (years)
Total urine
porphyrin
(nmol l1)
Total fecal
porphyrin
(nmol g1)
Plasma
porphyrin
(nmol l1)
Erythrocyte
porphyrin
(lmol l1)
Erythrocyte UROS
activity (% mean
control)
1 71 72 3,278 (79%) 718 (86%) 1501 2.42 (58%) 98
2 74 75 19,332 (82%) 1,413 (79%) Increased 5.3 (52%) 112
3 57 64 12,330 (69%) 2,628 (76%) 543 4.73 —
44 60 65 12,280 (97%) 1,655 — 1.9 —
Childhood-
onset CEP
No myeloid disorder o5 44,000 (7) 6,111 (7) 1,121 (15) 22.1 (15) 16–26 (3)
11,986–123,249 1,797–11,687 232–5,125 7.2–125.1
(NS)5 (P=0.02)5 (P=0.003)5
Reference
range
20–320 10–200 o11.2 0.4–1.7
Abbreviations: CEP, congenital erythropoietic porphyria; UROS, uroporphyrinogen III synthase.
Urinary and fecal porphyrin concentrations for childhood-onset CEP are for adults. Figures in parentheses are percent isomer I for uroporphyrin (urine) or
coproporphyrin (feces), percent zinc-protoporphyrin for erythrocyte porphyrin or, for CEP, number of patients. For CEP, figures are medians and ranges.
Fluorescence emission maxima for total plasma porphyrins were 617–618nm in all cases.
1Median of 12 measurements over 64 months; range 89–1,818 nmol l1.
2Median of 8 measurements over 64 months; range 1.3–14.3 mmol l1.
3Mainly zinc protoporphyrin.
4Data from the study by Murphy et al, 1995.
5Significance of difference between patient (patients 1–4) and CEP groups: NS, not significant. For methods, see Supplementary Materials and Methods
online.
www.jidonline.org 1173
RPE Sarkany et al.
Uroporphyria and Myeloid Disorders
from bone marrow as in peripheral
blood cells, excluding deletion of one
allele in the majority of marrow cell
nuclei. Mutations in GATA-1 on the
X chromosome may also cause CEP.
Karyotyping showed no X chromosome
abnormalities, and no GATA-1 muta-
tions were identified in genomic DNA
from peripheral blood (all four patients)
or from bone marrow (patient 1) by
sequencing or by denaturing high-per-
formance liquid chromatography (Sup-
plementary Methods online). Similar to
the fluorescence microscopic results,
these data suggest that any acquired
UROS or GATA1 mutation causing the
porphyria is unlikely to be present in a
high proportion of hemopoietic cells.
Our three patients bring the total
number of reported cases of erythro-
poietic uroporphyria associated with
myeloid malignancy to eight. All
were male patients, had a preexisting
myeloid disorder, and presented with
fragility and blistering in exposed skin
after the age of 50 years. Hemorrhagic
bullae in our four patients and in others
presumably reflect thrombocytopenia
(Kontos et al., 2003). None had ery-
throdontia, a feature of childhood CEP
also absent from the adult-onset her-
editary cases (Deybach et al., 1981).
None had a family history of CEP.
We have shown that these patients
have lower erythrocyte porphyrin con-
centrations compared with childhood
(Table 1) or adult-onset CEP (Deybach
et al., 1981) and that erythrocyte UROS
activity is normal (Table 1) in contrast
to the reduced activity in the hereditary
disease (Deybach et al., 1981; Desnick
and Astrin, 2002; de Verneuil et al.,
2003). We did not find germline muta-
tions in UROS or GATA1, in contrast
to hereditary CEP (Desnick and
Astrin, 2002; de Verneuil et al., 2003;
Phillips et al., 2007). These clinical and
pathological findings identify ‘‘uropor-
phyria associated with myeloid malig-
nancy’’ as a syndrome distinct from
hereditary CEP.
The low erythrocyte porphyrin and
normal UROS activity in our patients
suggest that only a small proportion of
circulating red cells are uroporphyric
and are consistent with the evidence
from bone marrow microscopy and cell
culture (Figure 1) that erythroid cells in
uroporphyria associated with MDS are
a mosaic of normal and uroporphyric
cells, with the former predomina-
ting. Acquired forms of a-thalassemia
(Steensma et al., 2005) and erythro-
poietic protoporphyria (Goodwin et al.,
2006) occurring in association with
MDS result from somatic mutations
in clones of myelodysplastic cells. It
seems probable that the minor clone of
uroporphyric erythropoietic cells in our
patients similarly contains an acquired
somatic mutation but one that leads to
UROS deficiency.
The cause of UROS deficiency in
uroporphyric cells remains to be identi-
fied. Our inability to find UROS or
GATA1 mutations may be explained by
the difficulty experienced in detec-
ting mosaicism when the proportion of
abnormal cells is low; the techniques we
used were unlikely to detect less than
B15% of mutant DNA. Alternatively, the
abnormality may be in another gene that
determines UROS activity.
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Figure 1. Fluorescence microscopic study of bone marrow and cells from burst-forming unit
(BFU)–erythroid colonies. Top: Bone marrow smear from patient 1 showing the same field under
fluorescence microscope (a) and stained with Wright–Giemsa stain to identify erythroid cells (b). Bottom:
Cells from BFU–erythroid colonies cultured from peripheral blood of patient 2. (c) Light microscopy.
(d) Fluorescence microscopy showing red porphyrin fluorescence. Cells from two different colonies are
shown. BFU–erythroid colonies were cultured from peripheral blood mononuclear cells (Supplementary
Materials and Methods online). For fluorescence microscopy, bone marrow smears or cells from
BFU–erythroid colonies were mounted in vectashield (Alpha Laboratories, Eastleigh, Hampshire, UK).
Photomicrographs were taken with a Zeiss Axioplan microscope (Carl Zeiss, Welwyn Garden City, UK)
using a tetramethylrhodamine isothiocyanate filter at 200 total magnification using a 20 /0.50
objective lens. Bar¼ 0.1mm.
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